Coherus Oncology (CHRS) Competitors

$1.07 0.00 (0.00%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.09 +0.02 (+1.87%)

As of 10/9/2026 07:45 PM Eastern

CHRS vs. CLYM, AURA, DBVT, AVBP, and STTK

Should you buy Coherus Oncology stock or one of its competitors? Coherus Oncology's main competitors and comparable companies include Climb Bio (CLYM), Aura Biosciences (AURA), DBV Technologies (DBVT), ArriVent BioPharma (AVBP), and Shattuck Labs (STTK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Coherus Oncology compare to Climb Bio?

Coherus Oncology (NASDAQ:CHRS) and Climb Bio (NASDAQ:CLYM) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and media sentiment.

In the previous week, Climb Bio had 2 more articles in the media than Coherus Oncology. MarketBeat recorded 3 mentions for Climb Bio and 1 mentions for Coherus Oncology. Climb Bio's average media sentiment score of 0.47 beat Coherus Oncology's score of 0.14 indicating that Climb Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Coherus Oncology	Neutral
Climb Bio	Neutral

72.8% of Coherus Oncology shares are held by institutional investors. Comparatively, 69.8% of Climb Bio shares are held by institutional investors. 7.2% of Coherus Oncology shares are held by insiders. Comparatively, 2.6% of Climb Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Climb Bio has a net margin of 0.00% compared to Coherus Oncology's net margin of -259.41%. Climb Bio's return on equity of -31.79% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coherus Oncology	-259.41%	-222.75%	-52.11%
Climb Bio	N/A	-31.79%	-30.79%

Coherus Oncology currently has a consensus target price of $11.00, suggesting a potential upside of 928.04%. Climb Bio has a consensus target price of $27.62, suggesting a potential upside of 151.05%. Given Coherus Oncology's higher possible upside, equities analysts plainly believe Coherus Oncology is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coherus Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

Coherus Oncology has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market. Comparatively, Climb Bio has a beta of -0.04, suggesting that its stock price is 104% less volatile than the broader market.

Coherus Oncology has higher revenue and earnings than Climb Bio. Climb Bio is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coherus Oncology	$50.94M	3.25	$168.02M	-$1.03	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.83	N/A

Summary

Climb Bio beats Coherus Oncology on 9 of the 16 factors compared between the two stocks.

How does Coherus Oncology compare to Aura Biosciences?

Coherus Oncology (NASDAQ:CHRS) and Aura Biosciences (NASDAQ:AURA) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

Coherus Oncology has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market. Comparatively, Aura Biosciences has a beta of 0.41, indicating that its share price is 59% less volatile than the broader market.

Aura Biosciences has a net margin of 0.00% compared to Coherus Oncology's net margin of -259.41%. Aura Biosciences' return on equity of -73.18% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coherus Oncology	-259.41%	-222.75%	-52.11%
Aura Biosciences	N/A	-73.18%	-62.00%

72.8% of Coherus Oncology shares are held by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are held by institutional investors. 7.2% of Coherus Oncology shares are held by company insiders. Comparatively, 1.9% of Aura Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Aura Biosciences had 1 more articles in the media than Coherus Oncology. MarketBeat recorded 2 mentions for Aura Biosciences and 1 mentions for Coherus Oncology. Aura Biosciences' average media sentiment score of 0.37 beat Coherus Oncology's score of 0.14 indicating that Aura Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Coherus Oncology	Neutral
Aura Biosciences	Neutral

Coherus Oncology has higher revenue and earnings than Aura Biosciences. Aura Biosciences is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coherus Oncology	$50.94M	3.25	$168.02M	-$1.03	N/A
Aura Biosciences	N/A	N/A	-$106.19M	-$1.75	N/A

Coherus Oncology currently has a consensus target price of $11.00, suggesting a potential upside of 928.04%. Aura Biosciences has a consensus target price of $17.50, suggesting a potential upside of 167.58%. Given Coherus Oncology's higher probable upside, equities research analysts plainly believe Coherus Oncology is more favorable than Aura Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coherus Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Aura Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Coherus Oncology beats Aura Biosciences on 8 of the 13 factors compared between the two stocks.

How does Coherus Oncology compare to DBV Technologies?

Coherus Oncology (NASDAQ:CHRS) and DBV Technologies (NASDAQ:DBVT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

Coherus Oncology currently has a consensus target price of $11.00, indicating a potential upside of 928.04%. DBV Technologies has a consensus target price of $48.50, indicating a potential upside of 394.90%. Given Coherus Oncology's higher possible upside, equities analysts clearly believe Coherus Oncology is more favorable than DBV Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coherus Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
DBV Technologies	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

72.8% of Coherus Oncology shares are owned by institutional investors. Comparatively, 71.7% of DBV Technologies shares are owned by institutional investors. 7.2% of Coherus Oncology shares are owned by insiders. Comparatively, 1.1% of DBV Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Coherus Oncology has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market. Comparatively, DBV Technologies has a beta of -1.04, meaning that its share price is 204% less volatile than the broader market.

In the previous week, DBV Technologies had 2 more articles in the media than Coherus Oncology. MarketBeat recorded 3 mentions for DBV Technologies and 1 mentions for Coherus Oncology. Coherus Oncology's average media sentiment score of 0.14 beat DBV Technologies' score of -0.91 indicating that Coherus Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
Coherus Oncology	Neutral
DBV Technologies	Negative

Coherus Oncology has a net margin of -259.41% compared to DBV Technologies' net margin of -3,506.53%. DBV Technologies' return on equity of -119.33% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coherus Oncology	-259.41%	-222.75%	-52.11%
DBV Technologies	-3,506.53%	-119.33%	-84.43%

Coherus Oncology has higher revenue and earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coherus Oncology	$50.94M	3.25	$168.02M	-$1.03	N/A
DBV Technologies	$5.64M	109.26	-$146.95M	-$3.51	N/A

Summary

Coherus Oncology beats DBV Technologies on 11 of the 16 factors compared between the two stocks.

How does Coherus Oncology compare to ArriVent BioPharma?

ArriVent BioPharma (NASDAQ:AVBP) and Coherus Oncology (NASDAQ:CHRS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability.

In the previous week, ArriVent BioPharma had 26 more articles in the media than Coherus Oncology. MarketBeat recorded 27 mentions for ArriVent BioPharma and 1 mentions for Coherus Oncology. Coherus Oncology's average media sentiment score of 0.14 beat ArriVent BioPharma's score of -0.42 indicating that Coherus Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
ArriVent BioPharma	Neutral
Coherus Oncology	Neutral

9.5% of ArriVent BioPharma shares are held by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are held by institutional investors. 8.6% of ArriVent BioPharma shares are held by insiders. Comparatively, 7.2% of Coherus Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

ArriVent BioPharma has a net margin of 0.00% compared to Coherus Oncology's net margin of -259.41%. ArriVent BioPharma's return on equity of -50.26% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ArriVent BioPharma	N/A	-50.26%	-46.66%
Coherus Oncology	-259.41%	-222.75%	-52.11%

ArriVent BioPharma has a beta of 1.34, suggesting that its share price is 34% more volatile than the broader market. Comparatively, Coherus Oncology has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market.

ArriVent BioPharma presently has a consensus target price of $27.44, suggesting a potential upside of 64.04%. Coherus Oncology has a consensus target price of $11.00, suggesting a potential upside of 928.04%. Given Coherus Oncology's higher probable upside, analysts clearly believe Coherus Oncology is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Coherus Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Coherus Oncology has higher revenue and earnings than ArriVent BioPharma. ArriVent BioPharma is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.62	N/A
Coherus Oncology	$50.94M	3.25	$168.02M	-$1.03	N/A

Summary

ArriVent BioPharma beats Coherus Oncology on 8 of the 15 factors compared between the two stocks.

How does Coherus Oncology compare to Shattuck Labs?

Shattuck Labs (NASDAQ:STTK) and Coherus Oncology (NASDAQ:CHRS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

Shattuck Labs has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market. Comparatively, Coherus Oncology has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market.

Coherus Oncology has higher revenue and earnings than Shattuck Labs. Shattuck Labs is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	599.15	-$48.81M	-$0.51	N/A
Coherus Oncology	$50.94M	3.25	$168.02M	-$1.03	N/A

58.7% of Shattuck Labs shares are held by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are held by institutional investors. 8.8% of Shattuck Labs shares are held by insiders. Comparatively, 7.2% of Coherus Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Shattuck Labs currently has a consensus target price of $13.33, suggesting a potential upside of 123.34%. Coherus Oncology has a consensus target price of $11.00, suggesting a potential upside of 928.04%. Given Coherus Oncology's higher probable upside, analysts plainly believe Coherus Oncology is more favorable than Shattuck Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
Coherus Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Shattuck Labs has a net margin of 0.00% compared to Coherus Oncology's net margin of -259.41%. Shattuck Labs' return on equity of -43.57% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-43.57%	-40.90%
Coherus Oncology	-259.41%	-222.75%	-52.11%

In the previous week, Shattuck Labs had 4 more articles in the media than Coherus Oncology. MarketBeat recorded 5 mentions for Shattuck Labs and 1 mentions for Coherus Oncology. Shattuck Labs' average media sentiment score of 0.52 beat Coherus Oncology's score of 0.14 indicating that Shattuck Labs is being referred to more favorably in the media.

Company	Overall Sentiment
Shattuck Labs	Positive
Coherus Oncology	Neutral

Summary

Shattuck Labs beats Coherus Oncology on 12 of the 17 factors compared between the two stocks.

Get Coherus Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CHRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CHRS vs. The Competition

Export

Metric	Coherus Oncology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$165.32M	$3.85B	$7.16B	$13.21B
Dividend Yield	N/A	3.66%	2.53%	16.37%
P/E Ratio	-1.04	13.62	275.30	26.16
Price / Sales	3.92	1,234.34	635.99	108.09
Price / Cash	N/A	116.56	76.38	53.09
Price / Book	2.14	17.17	11.22	6.33
Net Income	$168.02M	-$22.69M	$3.50B	$382.15M
7 Day Performance	-7.76%	-1.34%	-0.89%	-1.40%
1 Month Performance	-20.15%	-8.45%	-4.42%	-3.47%
1 Year Performance	-35.93%	14.02%	7.03%	1.18%

Coherus Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CHRS Coherus Oncology	1.4759 of 5 stars	$1.07 flat	$11.00 +928.0%	-41.2%	$165.32M	$42.17M	N/A	144	Analyst Downgrade
CLYM Climb Bio	2.3465 of 5 stars	$11.16 +1.0%	$27.62 +147.4%	+482.0%	$639.26M	N/A	N/A	29
AURA Aura Biosciences	2.1112 of 5 stars	$6.18 -0.6%	$17.50 +183.2%	+8.5%	$638.34M	N/A	N/A	113
DBVT DBV Technologies	3.5041 of 5 stars	$10.07 -3.6%	$48.50 +381.9%	-38.2%	$632.93M	N/A	N/A	161
AVBP ArriVent BioPharma	2.3444 of 5 stars	$12.85 -54.9%	$44.86 +249.2%	-20.8%	$625.35M	N/A	N/A	77	Trending News Analyst Forecast Analyst Revision High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CHRS) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Coherus Oncology (CHRS) Competitors

CHRS vs. CLYM, AURA, DBVT, AVBP, and STTK

How does Coherus Oncology compare to Climb Bio?

Summary

How does Coherus Oncology compare to Aura Biosciences?

Summary

How does Coherus Oncology compare to DBV Technologies?

Summary

How does Coherus Oncology compare to ArriVent BioPharma?

Summary

How does Coherus Oncology compare to Shattuck Labs?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CHRS vs. The Competition

Coherus Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Coherus Oncology (CHRS) Competitors

CHRS vs. CLYM, AURA, DBVT, AVBP, and STTK

How does Coherus Oncology compare to Climb Bio?

Does the media refer more to CHRS or CLYM?

Do institutionals and insiders hold more shares of CHRS or CLYM?

Is CHRS or CLYM more profitable?

Do analysts prefer CHRS or CLYM?

Which has more volatility & risk, CHRS or CLYM?

Which has better earnings and valuation, CHRS or CLYM?

Summary

How does Coherus Oncology compare to Aura Biosciences?

Which has more volatility and risk, CHRS or AURA?

Is CHRS or AURA more profitable?

Do institutionals and insiders have more ownership in CHRS or AURA?

Does the media prefer CHRS or AURA?

Which has better valuation and earnings, CHRS or AURA?

Do analysts rate CHRS or AURA?

Summary

How does Coherus Oncology compare to DBV Technologies?

Do analysts recommend CHRS or DBVT?

Do institutionals & insiders believe in CHRS or DBVT?

Which has more volatility and risk, CHRS or DBVT?

Does the media refer more to CHRS or DBVT?

Is CHRS or DBVT more profitable?

Which has preferable valuation and earnings, CHRS or DBVT?

Summary

How does Coherus Oncology compare to ArriVent BioPharma?

Does the media refer more to AVBP or CHRS?

Do insiders & institutionals have more ownership in AVBP or CHRS?

Is AVBP or CHRS more profitable?

Which has more volatility & risk, AVBP or CHRS?

Do analysts recommend AVBP or CHRS?

Which has preferable valuation & earnings, AVBP or CHRS?

Summary

How does Coherus Oncology compare to Shattuck Labs?

Which has more risk and volatility, STTK or CHRS?

Which has stronger earnings & valuation, STTK or CHRS?

Do institutionals and insiders hold more shares of STTK or CHRS?

Do analysts prefer STTK or CHRS?

Is STTK or CHRS more profitable?

Does the media favor STTK or CHRS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CHRS vs. The Competition

Coherus Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools